COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact

Trial results for two COVID-19 vaccines suggest at least 90% efficacy against symptomatic disease (VE(DIS)). It remains unknown whether this efficacy is mediated by lowering SARS-CoV-2 infection susceptibility (VE(SUSC)) or development of symptoms after infection (VE(SYMP)). We aim to assess and com...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Swan, David A., Bracis, Chloe, Janes, Holly, Moore, Mia, Matrajt, Laura, Reeves, Daniel B., Burns, Eileen, Donnell, Deborah, Cohen, Myron S., Schiffer, Joshua T., Dimitrov, Dobromir
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8324774/
https://ncbi.nlm.nih.gov/pubmed/34330945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-94719-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados